A Remarkable CAGR Of 13% To Be Witnessed By Atrial Fibrillation Devices Market Between 2020 to 2030
The Atrial Fibrillation Devices Market is
expected to be worth Expand Almost 4X at a CAGR of 13% between 2020
to 2030. Healthcare is going the “digital” way. In other words, artificial
intelligence (AI)-enabled medical devices and telemedicine are the concrete
instances of the proliferation of the digital wave in the healthcare industry.
This factor would be the one traversing the healthcare vertical in the forecast
period.
Interventional
electrophysiology devices have already had a significant impact on patients
suffering from cardiac arrhythmias, and are being increasingly adopted as a
permanent treatment option for atrial fibrillation. Procedures such as
radiofrequency ablation, cryoablation, and cox-maze are well performed in
today’s practice.
Recent studies have
found cryoablation to be more effective than medical management, and it is
widely used in medical surgical practice. The overall market is primarily
driven by the growing prevalence of atrial fibrillation amongst the geriatric
as well as adult population, and the adoption of minimally-invasive techniques
for the permanent treatment of atrial fibrillation.
Moreover, the use
of innovative techniques, advancements in technology, and favorable
reimbursement scenario are some other factors responsible for propelling the
growth of the atrial fibrillation devices market.
Planning Forward? Access Sample Of Atrial Fibrillation Devices Market
Report! https://www.persistencemarketresearch.co/samples/31531
Companies covered in Atrial Fibrillation Devices Market Report
·
Biosensense Webster, Inc. (Johnson & Johnson)
·
Abbott Laboratories
·
Medtronic Plc
·
Boston Scientific Corporation
·
AtriCure, Inc.
·
Japan Lifeline Co.
·
Biotronik, Inc
·
MicroPort Scientific Corporation
·
Biomerics
·
CathRx
How About
Revitalizing The Strategy-Oriented Funnel To Stay Ahead In The Atrial
Fibrillation Devices Market? https://www.persistencemarketresearch.co/methodology/31531
As such, the global
atrial fibrillation devices market is estimated to be valued at US$ 3.9
Bn in 2020, with the market expected to exhibit a healthy CAGR of more
than 14% during the forecast period (2020-2030).
Key Takeaways from Atrial Fibrillation Devices Market Study
·
The diagnostics segment, by product, is expected to gain maximum revenue
share over the forecast period. The therapeutic segment is anticipated to
increase at a CAGR of 15% over 2020–2030,
to reach US$ 8.3 Bn by 2030.
·
According to PMR data collected from electrophysiologists in various
regions, radiofrequency catheter ablation is the procedure of choice due to the
high success rate, while cryoablation is the second preference for atrial
fibrillation catheter ablation.
·
By technology, the radiofrequency and cryoablation segments,
collectively held more than 70% market share in terms of
revenue in 2019.
·
Among all end users, hospitals is the leading segment, which is followed
by cardiac catheterization laboratories. The hospitals segment is anticipated
to expand at a CAGR of 14% over the forecast period.
·
North America and Europe, collectively held more than 70% revenue
share in 2019, while South Asia is expected to show greater growth
potential over the forecast period.
·
With the ongoing Covid-19 pandemic wreaking havoc
across the world, other non-emergency treatments have been deprioritized. As
such in the near-term, the growth of the atrial fibrillation devices market
will be slower than the average for the decade ahead.
“New product approvals and launches of ablation catheters along with
increasing demand for minimally-invasive procedures offering increased
longevity and safety profiles are driving the growth of the global atrial
fibrillation devices market,” says a PMR analyst.
Planning To Introduce An Offbeat Product/Technology In The Atrial
Fibrillation Devices Market? Go To “Purchase Now” To Have Our Atrial
Fibrillation Devices Market Report! https://www.persistencemarketresearch.com/checkout/31531
New Product Launches – Key Strategic Focus of Market Players
Product approvals
by the FDA for new AF devices are responsible for intense competition among
market players. Numerous organizations are focusing on new product launches for
electrophysiology, especially for atrial fibrillation.
For instance,
in August 2016, Biosense Webster, Inc., a world leader in the
treatment and diagnosis of heart arrhythmias, announced the launch of
THERMOCOOL SMARTTOUCH SF catheters with contact force technology and a porous
tip designed to optimize the treatment of atrial fibrillation. Also, in January
2019, Abbott announced FDA approval for the TactiCath Contact Force
Ablation Catheter. These winning strategies by leading players in the atrial
fibrillation devices market are also being followed by regional and local
players.
Atrial Fibrillation Devices Market: Competition Landscape
The global market
is set to broaden its scope during the forecast period, stimulated by the
rising prevalence of AF, worldwide. In addition, a favorable reimbursement
scenario and increasing demand for minimally-invasive procedures have augmented
the sales of atrial fibrillation devices.
The market is
dominated by 4 major manufacturers – Biosense Webster, Inc.
(Johnson & Johnson), Abbott Laboratories, Medtronic Plc, and Boston
Scientific Corporation, with a revenue share of over 70% in 2019.
These major manufacturers are focusing on manufacturing electrophysiology
devices used specifically for atrial fibrillation procedure, such as ablation
devices, intracardiac echocardiography catheters, and left atrial appendage
(LAA) management devices.
Key market players
covered by PMR include Biosense Webster, Inc. (Johnson & Johnson), Abbott
Laboratories, Medtronic Plc, Boston Scientific Corporation, ArtiCure, Inc.,
Japan Lifeline Co., Biotronik SE & Co. KG, Biomerics, MicroPort
Corporation, and CathRx, who are consolidating their position through mergers,
acquisitions, and new product launches.
Want more insights?
PMR brings a
comprehensive research report on forecasted revenue growth at global, regional,
and country levels, and provides an analysis of the latest industry trends in
each of the sub-segments from 2015 to 2030. The
global atrial fibrillation devices market is segmented in detail to cover every
aspect of the market and present a complete market intelligence approach to the
reader.
The study provides
compelling insights on the atrial fibrillation devices market on basis of
product (diagnostics – conventional EP catheters, mapping catheters, CS
catheters, and ICE catheters) and therapeutics – EP ablation, maze surgery, and
LAA management devices), technology (radiofrequency, crythotherapy, ultrasound,
and others), and end user (hospitals, ambulatory surgical centers, and cardiac
catheterization laboratories), across seven major regions.
About Us :-
Persistence Market
Research is here to provide companies a one-stop solution with regards to
bettering customer experience. It does engage in gathering appropriate feedback
after getting through personalized customer interactions for adding value to
customers’ experience by acting as the “missing” link between “customer
relationships” and “business outcomes’. The best possible returns are assured
therein.
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
Comments
Post a Comment